EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect

Bart P Leroy, M Dominik Fischer, John G Flannery, Robert E MacLaren, Deniz Dalkara, Hendrik P N Scholl, Daniel C Chung, Claudio Spera, Daniel Viriato, Judit Banhazi

Ophthalmic Research · 2023 · 66 (1) · 179-196

DOI: 10.1159/000526317 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ophthalmic Research, online erschienen am 14.09.2022. Verfasst von Bart P Leroy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology & Centre for Medical Genetics, Ghent University Hospital & Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Genetic Vectors, Retinal Dystrophies. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent approval of voretigene neparvovec (Luxturna®) for patients with biallelic RPE65 mutation-associated inherited retinal dystrophy with viable retinal cells represents an important step in the development of ocular gene therapies. Herein, we review studies investigating the episomal persistence of different recombinant adeno-associated virus (rAAV) vector genomes and the preclinical and clinical evidence of long-term effects of different RPE65 gene replacement therapies. A targeted review of articles published between 1974 and January 2021 in Medline®, Embase®, and other databases was conducted, followed by a descriptive longitudinal analysis of the clinical trial outcomes of voretigene neparvovec. Following an initial screening, 14 publications examining the episomal persistence of different rAAV genomes and 71 publications evaluating gene therapies in animal models were included. Viral genomes were found to persist for at least 22 months (longest study follow-up) as transcriptionally active episomes. Treatment effects lasting almost a decade were reported in canine disease models, with more pronounced effects the earlier the intervention. The clinical trial outcomes of voretigene neparvovec are consistent with preclinical findings and reveal sustained results for up to 7.5 years for the full-field light sensitivity threshold test and 5 years for the multi-luminance mobility test in the Phase I and Phase III trials, respectively. In conclusion, the therapeutic effect of voretigene neparvovec lasts for at least a decade in animal models and 7.5 years in human subjects. Since retinal cells can retain functionality over their lifetime after transduction, these effects may be expected to last even longer in patients with a sufficient number of outer retinal cells at the time of intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic VectorsRetinal DystrophiesHumansAnimalsDogsRetinaGenetic TherapyVision, Ocularcis-trans-Isomerases

Stichwörter der Autor:innen

DurabilityGene therapyInherited retinal diseaseRPE65Viral vector

Substanzen

cis-trans-Isomerases

Autor:innen und Institutionen

  • Department of Ophthalmology & Centre for Medical Genetics, Ghent University Hospital & Ghent University, Ghent, Belgium.
  • Division of Ophthalmology & Center for Cellular & Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • University Eye Hospital, Centre for Ophthalmology, University Hospital Tübingen, Tübingen, Germany.
  • Oxford Eye Hospital, University of Oxford NHS Foundation Trust and NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • School of Optometry and the Helen Wills Neuroscience Institute, University of California-Berkeley, Berkeley, California, USA.

Zitieren

APA

Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023). Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect. Ophthalmic Research, 66(1), 179-196. https://doi.org/10.1159/000526317

Vancouver

Leroy BP, Fischer MD, Flannery JG, MacLaren RE, Dalkara D, Scholl HPN, et al. Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect. Ophthalmic Research. 2023;66(1):179-196. doi:10.1159/000526317

BibTeX
@article{Leroy2023,
  author = {Leroy, Bart P and Fischer, M Dominik and Flannery, John G and MacLaren, Robert E and Dalkara, Deniz and Scholl, Hendrik P N and Chung, Daniel C and Spera, Claudio and Viriato, Daniel and Banhazi, Judit},
  title = {Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect},
  journal = {Ophthalmic Research},
  year = {2023},
  volume = {66},
  number = {1},
  pages = {179--196},
  doi = {10.1159/000526317}
}
Kostenlos starten →